BioMarin Pharmaceuticals
BMRN
496 hedge funds and large institutions have $13.6B invested in BioMarin Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 63 funds opening new positions, 190 increasing their positions, 182 reducing their positions, and 93 closing their positions.
20% more call options, than puts
Call options by funds: $189M | Put options by funds: $158M
4% more repeat investments, than reductions
Existing positions increased: 190 | Existing positions reduced: 182
1.35% less ownership
Funds ownership: 100.31% → 98.96% (-1.4%)
6% less funds holding
Funds holding: 527 → 496 (-31)
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
32% less first-time investments, than exits
New positions opened: 63 | Existing positions closed: 93
39% less capital invested
Capital invested by funds: $22.3B → $13.6B (-$8.73B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$415M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$366M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$225M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$95.5M |
| 5 |
DLPIC
Davide Leone & Partners Investment Company
London,
United Kingdom
|
+$91.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$702M |
| 2 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$277M |
| 3 |
BlackRock
New York
|
-$134M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$133M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$119M |
BMRN Hedge Fund Activity: Q3 2020 in Review
496 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q3 2020, worth a combined $13.6B — down 39% from $22.3B a quarter earlier.
Sellers outnumbered buyers: 93 funds closed out of BMRN and 63 opened new positions — a net loss of 30 holders — while 182 trimmed existing stakes and 190 added.
The largest buyer was Dodge & Cox, adding an estimated $415M. The largest seller was Jennison Associates, cutting an estimated $702M.
- 496 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q3 2020, down from 527 in Q2 2020.
- Funds reported $13.6B of BioMarin Pharmaceuticals stock for Q3 2020, down 39% quarter-over-quarter.
- 63 funds opened new BioMarin Pharmaceuticals positions in Q3 2020 and 93 closed out, a net change of -30 holders.
- The largest BioMarin Pharmaceuticals buyer in Q3 2020 was Dodge & Cox, an estimated $415M added.
- The largest BioMarin Pharmaceuticals seller in Q3 2020 was Jennison Associates, an estimated $702M sold.
Based on aggregated 13F filings for Q3 2020.